QR Code

Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy

Alectinib has been approved as first-line treatment for anaplastic lymphoma kinase (ALK)-positive non-small cell lung carcinoma. Oncologists are also exploring the possibility of applying alectinib in the perioperative period. Here, we present a patient with locally advanced lung adenocarcinoma asso...

Full description

Saved in:
Main Authors: Peijun Cao, Qingchun Zhao, Yongwen Li, Ruifeng Shi, Guangsheng Zhu, Zihe Zhang, Hongbing Zhang, Minghui Liu, Sen Wei, Hongyu Liu, Jun Chen
Format: Artigo
Language:Inglês
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Pharmacology
Subjects:
EML4-ALK fusion gene
pulmonary adenocarcinoma
neoadjuvant therapy
alectinib
pseudoresistance
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1140894/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items